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EFFECT OF RECOMBINANT ERYTHROPOIETIN ON PERIPHERAL T LYMPHOCYTES 
Kouichi Hisatomi, MD, a Masanobu Nakao, MD, b Tadashi Isomura, MD, a Kenichi Kosuga, MD, a 
and Kyogo Itoh, MD, b Fukuoka, Japan 
Recombinant erythropoietin 1 has commonly been used 
to reduce the volume of homologous blood transfusion in 
patients undergoing cardiac opera-tions in Japan. We 2 
have reported that recombinant erythropoietin treatment 
not only increased levels of circulating erythrocytes but 
also improved indices of cell-mediated immunity, and we 3 
have suggested that it might help to ameliorate or prevent 
the impairment of immune function that can occur after 
cardiac operations. We subsequently administered recom- 
binant erythropoietin a dosage of 200 U/kg per day for 
7 days in a patient with postoperative rythroderma 
associated with pancytopenia fter a cardiac operation. 
The level of interleukin-2 production was also found to 
increase in association with lessening of symptoms. In the 
present study, we investigated the effect of recombinant 
erythropoietin on peripheral T cell response with the use 
of a reverse-transcriptase polymerase chain reaction (PCR), 
which has currently been acknowledged to detect cytoldnes 
in vitro in immunologic studies. Peripheral blood mononu- 
clear cells were obtained 7 days postoperatively from 10 
patients who underwent valvular operations. Five of the 
patients without complications were given recombinant 
erythropoietin a dosage of 100 U/kg for 7 days, and the 
other five patients were not. Samples were prepared by the 
Ficoll-Conray method. They were adjusted to a concentra- 
tion of 4 × 106 cells per milliliter and were incubated with 5, 
10, 50, or 100 U/ml of recombinant erythropoietin for 6 
hours at 37 ° C. Ribonucleic acid (RNA) was isolated by the 
RNAzol method (Biotecx Laboratories, Inc., Houston, 
Tex.). Cyclic deoxyribonucleic a id was prepared essentially 
as described by Becker, Quay, and Soukup. 4 The PCR 
primers used for this study were interleukin-2 primers 
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(sense primer: 5 ' -TGTACAGGATGCAACTCCTGT-  
CTT; antisense primer: 5'-GTI'AGTGTTGAGATGAT- 
GCTTTGAC). PCR was performed for 35 cycles. Reverse- 
transcriptase PCR-amplified messenger RNA was electro- 
phoresed in a 1.5% agarose gel and stained with ethidium 
bromidefi T cells separated from peripheral blood mononu- 
clear cells mixed with 5 or 10 U/ml of recombinant erythro- 
poietin did not express interleukin-2, whereas the samples 
mixed with 50 or 100 U/ml of recombinant erythropoietin 
had decreased expression regardless of whether patients 
received recombinant erythropoietin for 7 days after the 
operation. These findings suggest hat, at the messenger 
RNA level, recombinant erythropoietin may inhibit produc- 
tion of interleukin-2 from T cells in proportion to the dose. 
These results suggest hat further study will be needed to 
reveal the true effect of recombinant erythropoietin on 
cell-mediated immune responses. 
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